Harvoni: single-tablet option in hepatitis C

Gilead has launched Harvoni (ledipasvir/sofosbuvir), the first once-daily, single-tablet treatment for chronic hepatitis C.

by
Ledipasvir targets the HCV non-structural protein NS5A and sofosbuvir inhibits the HCV RNA-dependent RNA polymerase NS5B. SCIENCE PHOTO LIBRARY
Ledipasvir targets the HCV non-structural protein NS5A and sofosbuvir inhibits the HCV RNA-dependent RNA polymerase NS5B. SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package